Citations (128)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Kouji Tagawa, Yoshihiro Maruo, Yu Mimura & Shinichi Ikushiro. (2023) Effects of common genetic variants of human uridine diphosphate glucuronosyltransferase subfamilies on irinotecan glucuronidation. Toxicology Mechanisms and Methods 33:3, pages 197-205.
Read now
Read now
Dong Gui Hu, Robyn Meech, Ross A. McKinnon & Peter I. Mackenzie. (2014) Transcriptional regulation of human UDP-glucuronosyltransferase genes. Drug Metabolism Reviews 46:4, pages 421-458.
Read now
Read now
Kimie Sai & Yoshiro Saito. (2011) Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs. Expert Opinion on Drug Metabolism & Toxicology 7:8, pages 967-988.
Read now
Read now
Tingting Li, Yi Zheng, Feifei Fu, Hui Ji, Xijing Chen, Ying Zhao, Di Zhao, Ning Li & Lingli Zhang. (2011) Assessment of UDP-glucuronosyltransferase catalyzed formation of Picroside II glucuronide in microsomes of different species and recombinant UGTs. Xenobiotica 41:7, pages 530-537.
Read now
Read now
Swati Nagar & Rebecca L. Blanchard. (2006) Pharmacogenetics of Uridine Diphosphoglucuronosyltransferase (UGT) 1A Family Members and its Role in Patient Response to Irinotecan. Drug Metabolism Reviews 38:3, pages 393-409.
Read now
Read now
Shufeng Zhou, Eli Chan, Wei Duan, Min Huang & Yu-Zong Chen. (2005) Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance. Drug Metabolism Reviews 37:1, pages 41-213.
Read now
Read now
Articles from other publishers (122)
Tomohiro Shintani, Chiharu Imamura, Yukiko Ueyama-Toba, Jumpei Inui, Akira Watanabe & Hiroyuki Mizuguchi. (2023) Establishment of UGT1A1-knockout human iPS-derived hepatic organoids for UGT1A1-specific kinetics and toxicity evaluation. Molecular Therapy - Methods & Clinical Development 30, pages 429-442.
Crossref
Crossref
Dong Gui Hu, Shashikanth Marri, Julie-Ann Hulin, Ross A. McKinnon, Peter I. Mackenzie & Robyn Meech. (2022) The Somatic Mutation Landscape of UDP-Glycosyltransferase (UGT) Genes in Human Cancers. Cancers 14:22, pages 5708.
Crossref
Crossref
Zhe Wang, Xiaoyu Wang, Zhen Wang, Xiaoyu Fan, Mingrui Yan, Lili Jiang, Yangliu Xia, Jun Cao & Yong Liu. (2022) Prediction of Drug–Drug Interaction Between Dabrafenib and Irinotecan via UGT1A1-Mediated Glucuronidation. European Journal of Drug Metabolism and Pharmacokinetics 47:3, pages 353-361.
Crossref
Crossref
Shiew-Mei Huang, Ligong Chen & Kathleen M. Giacomini. 2022. Atkinson's Principles of Clinical Pharmacology. Atkinson's Principles of Clinical Pharmacology
303
322
.
Zheng Liu, Jennifer H. Martin, Winston Liauw, Sue-Anne McLachlan, Emma Link, Anetta Matera, Michael Thompson, Michael Jefford, Rod J. Hicks, Carleen Cullinane, Athena Hatzimihalis, Ian Campbell, Simone Crowley, Phillip J. Beale, Christos S. Karapetis, Timothy Price, Mathew E. Burge & Michael Michael. (2021) Evaluation of pharmacogenomics and hepatic nuclear imaging–related covariates by population pharmacokinetic models of irinotecan and its metabolites. European Journal of Clinical Pharmacology 78:1, pages 53-64.
Crossref
Crossref
Zhe Wang, Xiaoyu Wang, Zhen Wang, Yaqin Jia, Yuyi Feng, Lili Jiang, Yangliu Xia, Jun Cao & Yong Liu. (2021) In vitro inhibition of human UDP-glucuronosyltransferase (UGT) 1A1 by osimertinib, and prediction of in vivo drug-drug interactions. Toxicology Letters 348, pages 10-17.
Crossref
Crossref
Md Masud Parvez, Abdul Basit, Parth B. Jariwala, Zsuzsanna Gáborik, Emese Kis, Scott Heyward, Matthew R. Redinbo & Bhagwat Prasad. (2021) Quantitative Investigation of Irinotecan Metabolism, Transport, and Gut Microbiome Activation. Drug Metabolism and Disposition 49:8, pages 683-693.
Crossref
Crossref
Keishi Yamasaki, Muneaki Hidaka, Yohei Kawano, Yumiko Furuya, Hiroshige Ono & Kazuhiko Arimori. (2021) Possible roles of intestinal P-glycoprotein and cytochrome P450 3A on the limited oral absorption of irinotecan. Journal of Pharmacy and Pharmacology 73:2, pages 178-184.
Crossref
Crossref
E. E. J. Kasteel, K. Darney, N. I. Kramer, J. L. C. M. Dorne & L. S. Lautz. (2020) Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors. Archives of Toxicology 94:8, pages 2637-2661.
Crossref
Crossref
Lili Jiang, Li Wang, Zhongmin Zhang, Zhen Wang, Xiaoyu Wang, Shujuan Wang, Xiaowei Luan, Yangliu Xia & Yong Liu. (2019) The pharmacokinetic interaction between irinotecan and sunitinib. Cancer Chemotherapy and Pharmacology 85:2, pages 443-448.
Crossref
Crossref
Adrien Labriet, Éric Lévesque, Elena De Mattia, Erika Cecchin, Derek Jonker, Félix Couture, David Simonyan, Angela Buonadonna, Mario D’Andrea, Lyne Villeneuve, Giuseppe Toffoli & Chantal Guillemette. (2019) Combination of germline variations associated with survival of folinic acid, fluorouracil and irinotecan-treated metastatic colorectal cancer patients. Pharmacogenomics 20:17, pages 1179-1187.
Crossref
Crossref
Ali N. Chamseddine, Michel Ducreux, Jean-Pierre Armand, Xavier Paoletti, Tuvana Satar, Angelo Paci & Olivier Mir. (2019) Intestinal bacterial β-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity. Pharmacology & Therapeutics 199, pages 1-15.
Crossref
Crossref
Robyn Meech, Dong Gui Hu, Ross A. McKinnon, Siti Nurul Mubarokah, Alex Z. Haines, Pramod C. Nair, Andrew Rowland & Peter I. Mackenzie. (2019) The UDP-Glycosyltransferase (UGT) Superfamily: New Members, New Functions, and Novel Paradigms. Physiological Reviews 99:2, pages 1153-1222.
Crossref
Crossref
Kimberly Lapham, Jian Lin, Jonathan Novak, Christine Orozco, Mark Niosi, Li Di, Theunis C. Goosen, Sangwoo Ryu, Keith Riccardi, Heather Eng, Kimberly O. Cameron & Amit S. Kalgutkar. (2018)
6-Chloro-5-[4-(1-Hydroxycyclobutyl)Phenyl]-1
H
-Indole-3-Carboxylic Acid is a Highly Selective Substrate for Glucuronidation by UGT1A1, Relative to
β
-Estradiol
. Drug Metabolism and Disposition 46:12, pages 1836-1846.
Crossref
Crossref
Takanori Akazawa, Shinpei Yoshida, Shuichi Ohnishi, Takushi Kanazu, Makoto Kawai & Koji Takahashi. (2018) Application of Intestinal Epithelial Cells Differentiated from Human Induced Pluripotent Stem Cells for Studies of Prodrug Hydrolysis and Drug Absorption in the Small Intestine. Drug Metabolism and Disposition 46:11, pages 1497-1506.
Crossref
Crossref
Ang Chen, Xiaojing Zhou, Yi Cheng, Shuowen Tang, Mingyao Liu & Xin Wang. (2018) Design and optimization of the cocktail assay for rapid assessment of the activity of UGT enzymes in human and rat liver microsomes. Toxicology Letters 295, pages 379-389.
Crossref
Crossref
Anna Mróz, Izabela Ryska, Hanna Sominko, Anna Bejrowska & Zofia Mazerska. (2018) Drug-drug interaction potential of antitumor acridine agent C-1748: The substrate of UDP-glucuronosyltransferases 2B7, 2B17 and the inhibitor of 1A9 and 2B7. Pharmacological Reports 70:5, pages 972-980.
Crossref
Crossref
Femke M. de Man, Andrew K. L. Goey, Ron H. N. van Schaik, Ron H. J. Mathijssen & Sander Bins. (2018) Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. Clinical Pharmacokinetics 57:10, pages 1229-1254.
Crossref
Crossref
Qianqian Yu, Tao Zhang, Conghua Xie, Hong Qiu, Bo Liu, Liu Huang, Ping Peng, Jueping Feng, Jigui Chen, Aihua Zang & Xianglin Yuan. (2018) UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy. Cancer Chemotherapy and Pharmacology 82:1, pages 87-98.
Crossref
Crossref
Ling Xiao, Liangliang Zhu, Wenjuan Li, Conghu Li, Yunfeng Cao, Guangbo Ge & Xiaoyu Sun. (2018) New Insights into SN-38 Glucuronidation: Evidence for the Important Role of UDP Glucuronosyltransferase 1A9. Basic & Clinical Pharmacology & Toxicology 122:4, pages 424-428.
Crossref
Crossref
Zi-Miao Weng, Ping Wang, Guang-Bo Ge, Zi-Ru Dai, Da-Chang Wu, Li-Wei Zou, Tong-Yi Dou, Tong-Yan Zhang, Ling Yang & Jie Hou. (2017) Structure-activity relationships of flavonoids as natural inhibitors against E. coli β-glucuronidase. Food and Chemical Toxicology 109, pages 975-983.
Crossref
Crossref
Efrat DotanSteven J. CohenAlexander N. StarodubChristopher H. LieuWells A. MessersmithPamela S. SimpsonMichael J. GuarinoJohn L. MarshallRichard M. GoldbergJ. Randolph HechtWilliam A. WegenerRobert M. SharkeySerengulam V. GovindanDavid M. GoldenbergJordan D. Berlin. (2017) Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. Journal of Clinical Oncology 35:29, pages 3338-3346.
Crossref
Crossref
Johanna Troberg, Erkka Järvinen, Guang-Bo Ge, Ling Yang & Moshe Finel. (2016) UGT1A10 Is a High Activity and Important Extrahepatic Enzyme: Why Has Its Role in Intestinal Glucuronidation Been Frequently Underestimated?. Molecular Pharmaceutics 14:9, pages 2875-2883.
Crossref
Crossref
Xingdong Wang, Zhi Rao, Hongyan Qin, Guoqiang Zhang, Yanrong Ma, Yongwen Jin, Miao Han, Axi Shi, Yanping Wang & Xinan Wu. (2016) Effect of hesperidin on the pharmacokinetics of CPT-11 and its active metabolite SN-38 by regulating hepatic Mrp2 in rats. Biopharmaceutics & Drug Disposition 37:7, pages 421-432.
Crossref
Crossref
Zofia Mazerska, Anna Mróz, Monika Pawłowska & Ewa Augustin. (2016) The role of glucuronidation in drug resistance. Pharmacology & Therapeutics 159, pages 35-55.
Crossref
Crossref
Nan Zhang, Yong Liu & Hyunyoung Jeong. (2015) Drug-Drug Interaction Potentials of Tyrosine Kinase Inhibitors via Inhibition of UDP-Glucuronosyltransferases. Scientific Reports 5:1.
Crossref
Crossref
Jacqueline Ramírez, Snezana Mirkov, Larry K. House & Mark J. Ratain. (2015) Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10. Drug Metabolism and Disposition 43:7, pages 928-935.
Crossref
Crossref
Boram Lee, Hyeon-Kyeong Ji, Taeho Lee & Kwang-Hyeon Liu. (2015) Simultaneous Screening of Activities of Five Cytochrome P450 and Four Uridine 5′-Diphospho-glucuronosyltransferase Enzymes in Human Liver Microsomes Using Cocktail Incubation and Liquid Chromatography–Tandem Mass Spectrometry. Drug Metabolism and Disposition 43:7, pages 1137-1146.
Crossref
Crossref
Wei Li, Yafei Xing & Yong Liu. (2015) Inhibition of SN-38 glucuronidation by gefitinib and its metabolite. Cancer Chemotherapy and Pharmacology 75:6, pages 1253-1260.
Crossref
Crossref
JuHee Sim, Woongsik Nam, Doohyun Lee, Suyoun Lee, Hungchan O, Jeongmin Joo, Kwang-Hyeon Liu, Jae Yun Han, Sung Hwan Ki, Tae Cheon Jeong, Taeho Lee & Sangkyu Lee. (2014) Selective induction of hepatic cytochrome P450 2B activity by leelamine in vivo, as a potent novel inducer. Archives of Pharmacal Research 38:5, pages 725-733.
Crossref
Crossref
Jeongmin Joo, Yang-Weon Kim, Zhexue Wu, Jung-Hoon Shin, Boram Lee, Jong Cheol Shon, Eun Young Lee, Nguyen Minh Phuc & Kwang-Hyeon Liu. (2015) Screening of non-steroidal anti-inflammatory drugs for inhibitory effects on the activities of six UDP-glucuronosyltransferases (UGT1A1, 1A3, 1A4, 1A6, 1A9 and 2B7) using LC-MS/MS. Biopharmaceutics & Drug Disposition 36:4, pages 258-264.
Crossref
Crossref
Yoshiko Kaku, Ayako Tsuchiya, Takeshi Kanno & Tomoyuki Nishizaki. (2015) Irinotecan Induces Cell Cycle Arrest, but Not Apoptosis or Necrosis, in Caco-2 and CW2 Colorectal Cancer Cell Lines. Pharmacology 95:3-4, pages 154-159.
Crossref
Crossref
Jeongmin Joo, Boram Lee, Taeho Lee & Kwang-Hyeon Liu. (2014) Screening of six UGT enzyme activities in human liver microsomes using liquid chromatography/triple quadrupole mass spectrometry. Rapid Communications in Mass Spectrometry 28:22, pages 2405-2414.
Crossref
Crossref
Kyung-Ah Seo, Hyo-Ji Kim, Eun Sook Jeong, Nagi Abdalla, Chang-Soo Choi, Dong-Hyun Kim & Jae-Gook Shin. (2014) In Vitro Assay of Six UDP-Glucuronosyltransferase Isoforms in Human Liver Microsomes, Using Cocktails of Probe Substrates and Liquid Chromatography–Tandem Mass Spectrometry. Drug Metabolism and Disposition 42:11, pages 1803-1810.
Crossref
Crossref
Wanqing Liu, Jacqueline Ram?rez, Eric R. Gamazon, Snezana Mirkov, Peixian Chen, Kehua Wu, Chang Sun, Nancy J. Cox, Edwin CookJrJr, Soma Das & Mark J. Ratain. (2014) Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver. Human Molecular Genetics 23:20, pages 5558-5569.
Crossref
Crossref
Huijuan WangTing BianTianbo JinYong Chen, Aifen Lin & Chao Chen. (2014)
Association analysis of
UGT1A
genotype and haplotype with SN-38 glucuronidation in human livers
. Pharmacogenomics 15:6, pages 785-798.
Crossref
Crossref
Yuji Ishii, Hiroki Koba, Kousuke Kinoshita, Toshiya Oizaki, Yuki Iwamoto, Shuso Takeda, Yuu Miyauchi, Yoshio Nishimura, Natsuki Egoshi, Futoshi Taura, Satoshi Morimoto, Shin’ichi Ikushiro, Kiyoshi Nagata, Yasushi Yamazoe, Peter I. Mackenzie & Hideyuki Yamada. (2014) Alteration of the Function of the UDP-Glucuronosyltransferase 1A Subfamily by Cytochrome P450 3A4: Different Susceptibility for UGT Isoforms and UGT1A1/7 Variants. Drug Metabolism and Disposition 42:2, pages 229-238.
Crossref
Crossref
Beatrice Mohelnikova-Duchonova. (2014) FOLFOX/FOLFIRI pharmacogenetics: The call for a personalized approach in colorectal cancer therapy. World Journal of Gastroenterology 20:30, pages 10316.
Crossref
Crossref
J.C. Stingl, H. Bartels, R. Viviani, M.L. Lehmann & J. Brockmöller. (2014) Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review. Pharmacology & Therapeutics 141:1, pages 92-116.
Crossref
Crossref
Michael Tagen & Clinton F. Stewart. 2014. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics
625
659
.
E. Levesque, A.-S. Belanger, M. Harvey, F. Couture, D. Jonker, F. Innocenti, E. Cecchin, G. Toffoli & C. Guillemette. (2013) Refining the UGT1A Haplotype Associated with Irinotecan-Induced Hematological Toxicity in Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Irinotecan-Based Regimens. Journal of Pharmacology and Experimental Therapeutics 345:1, pages 95-101.
Crossref
Crossref
Yuuka Miyake, Kei Mayumi, Hideto Jinno, Toshiko Tanaka-Kagawa, Shizuo Narimatsu & Nobumitsu Hanioka. (2013) cDNA Cloning and Functional Analysis of Minipig Uridine Diphosphate-Glucuronosyltransferase 1A1. Biological and Pharmaceutical Bulletin 36:3, pages 452-461.
Crossref
Crossref
Laurie D. DeLeve. 2013. Drug-Induced Liver Disease. Drug-Induced Liver Disease
541
567
.
Alexander V. LyubimovRobert S. Foti, Dan A. Rock, Larry C. Wienkers & Jan L. Wahlstrom. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
68
.
Lucía Cortejoso & Luis A López-Fernández. (2012) Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients. Pharmacogenomics 13:10, pages 1173-1191.
Crossref
Crossref
Nobumitsu Hanioka, Hiroyuki Iwabu, Hiroyuki Hanafusa, Shintaro Nakada & Shizuo Narimatsu. (2011) Expression and Inducibility of UDP‐glucuronosyltransferase 1As in MCF‐7 Human Breast Carcinoma Cells. Basic & Clinical Pharmacology & Toxicology 110:3, pages 253-258.
Crossref
Crossref
Alexander V. LyubimovRobert S. Foti & Michael B. Fisher. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
71
.
Kaoru Kobayashi, Akane Yoshida, Yoko Ejiri, Sachiko Takagi, Hanaka Mimura, Masaya Hosoda, Tomokazu Matsuura & Kan Chiba. (2012) Increased Expression of Drug-metabolizing Enzymes in Human Hepatocarcinoma FLC-4 Cells Cultured on Micro-space Cell Culture Plates. Drug Metabolism and Pharmacokinetics 27:5, pages 478-485.
Crossref
Crossref
Shiew-Mei Huang, Ligong Chen & Kathleen M. Giacomini. 2012. Principles of Clinical Pharmacology. Principles of Clinical Pharmacology
285
306
.
Joanne Siok Liu Lim, Sin Chi Chew & Balram Chowbay. 2012. Genomics Applications for the Developing World. Genomics Applications for the Developing World
183
214
.
Beverly A. Teicher. 2012. DNA Topoisomerases and Cancer. DNA Topoisomerases and Cancer
185
210
.
Baojian Wu, Shuxing Zhang & Ming Hu. (2011)
Evaluation of 3,3′,4′-Trihydroxyflavone and 3,6,4′-Trihydroxyflavone (4′-
O
-Glucuronidation) as the in Vitro Functional Markers for Hepatic UGT1A1
. Molecular Pharmaceutics 8:6, pages 2379-2389.
Crossref
Crossref
Annabelle Ballesta, Sandrine Dulong, Chadi Abbara, Boris Cohen, Alper Okyar, Jean Clairambault & Francis Levi. (2011) A Combined Experimental and Mathematical Approach for Molecular-based Optimization of Irinotecan Circadian Delivery. PLoS Computational Biology 7:9, pages e1002143.
Crossref
Crossref
Ana I. Loureiro, Carlos Fernandes-Lopes, Maria J. Bonifácio, Lyndon C. Wright & Patricio Soares-da-Silva. (2011) Hepatic UDP-Glucuronosyltransferase Is Responsible for Eslicarbazepine Glucuronidation. Drug Metabolism and Disposition 39:9, pages 1486-1494.
Crossref
Crossref
Jin Zhou, Timothy S. Tracy & Rory P. Remmel. (2011) Correlation between Bilirubin Glucuronidation and Estradiol-3-Gluronidation in the Presence of Model UDP-Glucuronosyltransferase 1A1 Substrates/Inhibitors. Drug Metabolism and Disposition 39:2, pages 322-329.
Crossref
Crossref
Anne-Sophie Bélanger, Jelena Tojcic, Mario Harvey & Chantal Guillemette. (2010) Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells. BMC Molecular Biology 11:1.
Crossref
Crossref
J Bellemare, M Rouleau, M Harvey, B Têtu & C Guillemette. (2009) Alternative-splicing forms of the major phase II conjugating UGT1A gene negatively regulate glucuronidation in human carcinoma cell lines. The Pharmacogenomics Journal 10:5, pages 431-441.
Crossref
Crossref
Nobumitsu Hanioka, Natsuko Tanabe, Hideto Jinno, Toshiko Tanaka-Kagawa, Kenjiro Nagaoka, Shinsaku Naito, Akiko Koeda & Shizuo Narimatsu. (2010) Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sciences 87:7-8, pages 261-268.
Crossref
Crossref
Yong Liu, Jacqueline Ram?rez, Larry House & Mark J. Ratain. (2010) The UGT1A1?28 polymorphism correlates with erlotinib?s effect on SN-38 glucuronidation. European Journal of Cancer 46:11, pages 2097-2103.
Crossref
Crossref
Jacqueline RamírezMark J RatainFederico Innocenti. (2010) Uridine 5´-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncology 6:4, pages 563-585.
Crossref
Crossref
Shirley S Brill, Anna M Furimsky, Mark N Ho, Michael J Furniss, Yi Li, Adam G Green, Carol E Green, Lalitha V Iyer, Wallace W Bradford & Izet M Kapetanovic. (2006)
Glucuronidation of
trans
-resveratrol by human liver and intestinal microsomes and UGT isoforms
. Journal of Pharmacy and Pharmacology 58:4, pages 469-479.
Crossref
Crossref
Shu-Feng Zhou. 2010. Supportive Cancer Care with Chinese Medicine. Supportive Cancer Care with Chinese Medicine
293
340
.
Yang Lu, Jing Zhu, Xijing Chen, Ning Li, Feifei Fu, Jiake He, Guangji Wang, Lingli Zhang, Yi Zheng, Zhixia Qiu, Xue Yu, Deen Han & Lei Wu. (2009) Identification of Human UDP-Glucuronosyltransferase Isoforms Responsible for the Glucuronidation of Glycyrrhetinic Acid. Drug Metabolism and Pharmacokinetics 24:6, pages 523-528.
Crossref
Crossref
Dinemarie Kweekel, Henk-Jan Guchelaar & Hans Gelderblom. (2008) Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treatment Reviews 34:7, pages 656-669.
Crossref
Crossref
Minoli A. Perera, Federico Innocenti & Mark J. Ratain. (2012) Pharmacogenetic Testing for Uridine Diphosphate Glucuronosyltransferase 1A1 Polymorphisms: Are We There Yet?. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 28:6, pages 755-768.
Crossref
Crossref
Nobumitsu Hanioka, Yuri Takeda, Toshiko Tanaka-Kagawa, Keiko Hayashi, Hideto Jinno & Shizuo Narimatsu. (2008) Interaction of bisphenol a with human UDP-glucuronosyltransferase 1A6 enzyme. Environmental Toxicology 23:3, pages 407-412.
Crossref
Crossref
Kimie SAI, Jun-ichi SAWADA & Hironobu MINAMI. (2008) Irinotecan Pharmacogenetics in Japanese Cancer Patients: Roles of <i>UGT1A1<sup>*</sup>6</i> and <sup>*</sup><i>28</i>日本人がん患者のイリノテカン個別化治療実現に向けて：<i>UGT1A1</i>遺伝子多型（<sup>*</sup><i>28</i>及び<sup>*</sup><i>6</i>）の意義について. YAKUGAKU ZASSHI 128:4, pages 575-584.
Crossref
Crossref
Takenori Takahata, Keizou Ookawa, Koji Suto, Masanori Tanaka, Hirohisa Yano, Osamu Nakashima, Masamichi Kojiro, Yoshihiro Tamura, Tomonori Tateishi, Yuh Sakata & Shinsaku Fukuda. (2008) Chemosensitivity Determinants of Irinotecan Hydrochloride in Hepatocellular Carcinoma Cell Lines. Basic & Clinical Pharmacology & Toxicology 102:4, pages 399-407.
Crossref
Crossref
Kimie Sai, Yoshiro Saito, Hiromi Sakamoto, Kuniaki Shirao, Koichi Kurose, Mayumi Saeki, Shogo Ozawa, Nahoko Kaniwa, Setsuo Hirohashi, Nagahiro Saijo, Jun-ichi Sawada & Teruhiko Yoshida. (2008) Importance of UDP-glucuronosyltransferase 1A1?6 for irinotecan toxicities in Japanese cancer patients. Cancer Letters 261:2, pages 165-171.
Crossref
Crossref
Ryoichi Fujiwara, Miki Nakajima, Hiroyuki Yamanaka, Miki Katoh & Tsuyoshi Yokoi. (2008) Product Inhibition of UDP-Glucuronosyltransferase (UGT) Enzymes by UDP Obfuscates the Inhibitory Effects of UGT Substrates. Drug Metabolism and Disposition 36:2, pages 361-367.
Crossref
Crossref
Lars M. Wagner, Kristine R. Crews, Clinton F. Stewart, Carlos Rodriguez‐Galindo, Rene Y. McNall‐Knapp, Karen Albritton, Alberto S. Pappo & Wayne L. Furman. (2007) Reducing irinotecan‐associated diarrhea in children. Pediatric Blood & Cancer 50:2, pages 201-207.
Crossref
Crossref
Kimie Sai, Hironobu Minami, Yoshiro Saito & Jun-ichi Sawada. 2009. Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response. Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response
267
286
.
Marissa A. Schiel, Scheri-lyn Green, Wilhelmina I. Davis, Paresh C. Sanghani, William F. Bosron & Sonal P. Sanghani. (2007) Expression and Characterization of a Human Carboxylesterase 2 Splice Variant. Journal of Pharmacology and Experimental Therapeutics 323:1, pages 94-101.
Crossref
Crossref
Yuji Mano, Takashi Usui & Hidetaka Kamimura. (2007) Substrate-Dependent Modulation of UDP-Glucuronosyltransferase 1A1 (UGT1A1) by Propofol in Recombinant Human UGT1A1 and Human Liver Microsomes. Basic & Clinical Pharmacology & Toxicology 101:3, pages 211-214.
Crossref
Crossref
Russell P. Kruzelock & William Short. (2007) Colorectal Cancer Therapeutics and the Challenges of Applied Pharmacogenomics. Current Problems in Cancer 31:5, pages 315-366.
Crossref
Crossref
Andrea L. Yoder Graber, Jacqueline Ramírez, Federico Innocenti & Mark J. Ratain. (2007) UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers. Pharmacogenetics and Genomics 17:8, pages 619-627.
Crossref
Crossref
Ken-ichi Fujita, Yuichi Ando, Fumio Nagashima, Wataru Yamamoto, Hisashi Eodo, Kazuhiro Araki, Keiji Kodama, Toshimichi Miya, Masaru Narabayashi & Yasutsuna Sasaki. (2007) Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer. Cancer Chemotherapy and Pharmacology 60:4, pages 515-522.
Crossref
Crossref
. 2007. Drug-Induced Liver Disease, Second Edition. Drug-Induced Liver Disease, Second Edition
631
662
.
Hironobu Minami, Kimie Sai, Mayumi Saeki, Yoshiro Saito, Shogo Ozawa, Kazuhiro Suzuki, Nahoko Kaniwa, Jun-ichi Sawada, Tetsuya Hamaguchi, Noboru Yamamoto, Kuniaki Shirao, Yasuhide Yamada, Hironobu Ohmatsu, Kaoru Kubota, Teruhiko Yoshida, Atsushi Ohtsu & Nagahiro Saijo. (2007) Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenetics and Genomics 17:7, pages 497-504.
Crossref
Crossref
Yusuke Hara, Miki Nakajima, Ken-ichi Miyamoto & Tsuyoshi Yokoi. (2007) Morphine Glucuronosyltransferase Activity in Human Liver Microsomes is Inhibited by a Variety of Drugs that are Co-administered with Morphine. Drug Metabolism and Pharmacokinetics 22:2, pages 103-112.
Crossref
Crossref
K. Mross, S. Steinbild, F. Baas, D. Gmehling, M. Radtke, D. Voliotis, E. Brendel, O. Christensen & C. Unger. (2007) Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. European Journal of Cancer 43:1, pages 55-63.
Crossref
Crossref
Federico InnocentiMark J Ratain. (2006) Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics 7:8, pages 1211-1221.
Crossref
Crossref
Jean Abraham, Helena M. Earl, Paul D. Pharoah & Carlos Caldas. (2006) Pharmacogenetics of cancer chemotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1766:2, pages 168-183.
Crossref
Crossref
J. Mercke Odeberg, J. Andrade, K. Holmberg, P. Hoglund, U. Malmqvist & J. Odeberg. (2006) UGT1A polymorphisms in a Swedish cohort and a human diversity panel, and the relation to bilirubin plasma levels in males and females. European Journal of Clinical Pharmacology 62:10, pages 829-837.
Crossref
Crossref
Nobumitsu Hanioka, Nobuhiko Obika, Masuhiro Nishimura, Hideto Jinno, Toshiko Tanaka-Kagawa, Keita Saito, Kimio Kiryu, Shinsaku Naito & Shizuo Narimatsu. (2006) Inducibility of UDP-glucuronosyltransferase 1As by β-naphthoflavone in HepG2 cells. Food and Chemical Toxicology 44:8, pages 1251-1260.
Crossref
Crossref
Hugo Girard, Lyne Villeneuve, Michael H. Court, Louis-Charles Fortier, Patrick Caron, Qin Hao, Lisa L. von Moltke, David J. Greenblatt & Chantal Guillemette. (2006) THE NOVEL UGT1A9 INTRONIC I399 POLYMORPHISM APPEARS AS A PREDICTOR OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN GLUCURONIDATION LEVELS IN THE LIVER. Drug Metabolism and Disposition 34:7, pages 1220-1228.
Crossref
Crossref
Federico Innocenti, Everett E. Vokes & Mark J. Ratain. (2006) Irinogenetics: What Is the Right Star?. Journal of Clinical Oncology 24:15, pages 2221-2224.
Crossref
Crossref
Jean-François Gagnon, Olivier Bernard, Lyne Villeneuve, Bernard Têtu & Chantal Guillemette. (2006)
Irinotecan Inactivation Is Modulated by Epigenetic Silencing of
UGT1A1
in Colon Cancer
. Clinical Cancer Research 12:6, pages 1850-1858.
Crossref
Crossref
Floris A. de Jong, Maja J.A. de Jonge, Jaap Verweij & Ron H.J. Mathijssen. (2006) Role of pharmacogenetics in irinotecan therapy. Cancer Letters 234:1, pages 90-106.
Crossref
Crossref
Jacqueline Ramírez, Bernard J. Komoroski, Snezana Mirkov, Andrea Yoder Graber, Donna Lee Fackenthal, Erin G. Schuetz, Soma Das, Mark J. Ratain, Federico Innocenti & Stephen C. Strom. (2006) Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes. Pharmacogenetics and Genomics 16:2, pages 79-86.
Crossref
Crossref
Yuji Mano, Takashi Usui & Hidetaka Kamimura. (2005)
In vitro
inhibitory effects of non‐steroidal anti‐inflammatory drugs on 4‐methylumbelliferone glucuronidation in recombinant human UDP‐glucuronosyltransferase 1A9—potent inhibition by niflumic acid
. Biopharmaceutics & Drug Disposition 27:1, pages 1-6.
Crossref
Crossref
Melanie N. Tallman, Joseph K. Ritter & Philip C. Smith. (2005) DIFFERENTIAL RATES OF GLUCURONIDATION FOR 7-ETHYL-10-HYDROXY-CAMPTOTHECIN (SN-38) LACTONE AND CARBOXYLATE IN HUMAN AND RAT MICROSOMES AND RECOMBINANT UDP-GLUCURONOSYLTRANSFERASE ISOFORMS. Drug Metabolism and Disposition 33:7, pages 977-983.
Crossref
Crossref
Gwendolyn E. Kuehl, Johanna W. Lampe, John D. Potter & Jeannette Bigler. (2005) GLUCURONIDATION OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS: IDENTIFYING THE ENZYMES RESPONSIBLE IN HUMAN LIVER MICROSOMES. Drug Metabolism and Disposition 33:7, pages 1027-1035.
Crossref
Crossref
Zeping Hu, Xiaoxia Yang, Paul Chi-Liu Ho, Eli Chan, Sui Yung Chan, Congjian Xu, Xiaotian Li, Yi-Zhun Zhu, Wei Duan, Xiao Chen, Min Huang, Hongyuan Yang & Shufeng Zhou. (2005) St. John’s Wort Modulates the Toxicities and Pharmacokinetics of CPT-11 (Irinotecan) in Rats. Pharmaceutical Research 22:6, pages 902-914.
Crossref
Crossref
Federico Innocenti, Wanqing Liu, Peixian Chen, Apurva A. Desai, Soma Das & Mark J. Ratain. (2005) Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenetics and Genomics 15:5, pages 295-301.
Crossref
Crossref
Qingyu Zhou, Alex Sparreboom, Eng-Huat Tan, Yin-Bun Cheung, Ann Lee, Donald Poon, Edmund J. D. Lee & Balram Chowbay. (2005) Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. British Journal of Clinical Pharmacology 59:4, pages 415-424.
Crossref
Crossref
Nahoko Kaniwa, Kouichi Kurose, Hideto Jinno, Toshiko Tanaka-Kagawa, Yoshiro Saito, Mayumi Saeki, Jun-ichi Sawada, Masahiro Tohkin & Ryuichi Hasegawa. (2005)
RACIAL VARIABILITY IN HAPLOTYPE FREQUENCIES OF
UGT1A1
AND GLUCURONIDATION ACTIVITY OF A NOVEL SINGLE NUCLEOTIDE POLYMORPHISM 686C> T (P229L) FOUND IN AN AFRICAN-AMERICAN
. Drug Metabolism and Disposition 33:3, pages 458-465.
Crossref
Crossref
Leslie E. Carlini, Neal J. Meropol, John Bever, Michael L. Andria, Todd Hill, Philip Gold, Andre Rogatko, Hao Wang & Rebecca L. Blanchard. (2005) UGT1A7 and UGT1A9 Polymorphisms Predict Response and Toxicity in Colorectal Cancer Patients Treated with Capecitabine/Irinotecan. Clinical Cancer Research 11:3, pages 1226-1236.
Crossref
Crossref
Mayumi Saeki, Yoshiro Saito, Hideto Jinno, Kimie Sai, Nahoko Kaniwa, Shogo Ozawa, Kazuo Komamura, Takeshi Kotake, Hideki Morishita, Shiro Kamakura, Masafumi Kitakaze, Hitonobu Tomoike, Kuniaki Shirao, Hironobu Minami, Atsushi Ohtsu, Teruhiko Yoshida, Nagahiro Saijo, Naoyuki Kamatani & Jun-ichi Sawada. (2005) Genetic Polymorphisms of UGT1A6 in a Japanese Population. Drug Metabolism and Pharmacokinetics 20:1, pages 85-90.
Crossref
Crossref
Hiroyuki Yamanaka, Miki Nakajima, Miki Katoh, Ayano Kanoh, Osamu Tamura, Hiroyuki Ishibashi & Tsuyoshi Yokoi. (2005)
TRANS
-3′-HYDROXYCOTININE
O
- AND
N
-GLUCURONIDATIONS IN HUMAN LIVER MICROSOMES
. Drug Metabolism and Disposition 33:1, pages 23-30.
Crossref
Crossref
Yuji Mano, Takashi Usui & Hidetaka Kamimura. (2004)
In Vitro
inhibitory effects of non‐steroidal antiinflammatory drugs on UDP‐glucuronosyltransferase 1A1‐catalysed estradiol 3
β
‐glucuronidation in human liver microsomes
. Biopharmaceutics & Drug Disposition 26:1, pages 35-39.
Crossref
Crossref
Yuji Mano, Takashi Usui & Hidetaka Kamimura. (2004)
Effects of
β
‐estradiol and propofol on the 4‐methylumbelliferone glucuronidation in recombinant human UGT isozymes 1A1, 1A8 and 1A9
. Biopharmaceutics & Drug Disposition 25:8, pages 339-344.
Crossref
Crossref
Floris A. de Jong, Sharon Marsh, Ron H. J. Mathijssen, Cristi King, Jaap Verweij, Alex Sparreboom & Howard L. McLeod. (2004) ABCG2 Pharmacogenetics. Clinical Cancer Research 10:17, pages 5889-5894.
Crossref
Crossref
Eszter Hazai, Peter V. Gagne & David Kupfer. (2004) GLUCURONIDATION OF THE OXIDATIVE CYTOCHROME P450-MEDIATED PHENOLIC METABOLITES OF THE ENDOCRINE DISRUPTOR PESTICIDE: METHOXYCHLOR BY HUMAN HEPATIC UDP-GLUCURONOSYL TRANSFERASES. Drug Metabolism and Disposition 32:7, pages 742-751.
Crossref
Crossref
Alex Sparreboom, Michael C. Cox, Milin R. Acharya & William D. Figg. (2004) Herbal Remedies in the United States: Potential Adverse Interactions With Anticancer Agents. Journal of Clinical Oncology 22:12, pages 2489-2503.
Crossref
Crossref
Sonal P. Sanghani, Sara K. Quinney, Tyler B. Fredenburg, Wilhelmina I. Davis, Daryl J. Murry & William F. Bosron. (2004)
HYDROLYSIS OF IRINOTECAN AND ITS OXIDATIVE METABOLITES, 7-ETHYL-10-[4-
N
-(5-AMINOPENTANOIC ACID)-1-PIPERIDINO] CARBONYLOXYCAMPTOTHECIN AND 7-ETHYL-10-[4-(1-PIPERIDINO)-1-AMINO]-CARBONYLOXYCAMPTOTHECIN, BY HUMAN CARBOXYLESTERASES CES1A1, CES2, AND A NEWLY EXPRESSED CARBOXYLESTERASE ISOENZYME, CES3
. Drug Metabolism and Disposition 32:5, pages 505-511.
Crossref
Crossref
Hiroyuki Yamanaka, Miki Nakajima, Miki Katoh, Yusuke Hara, Osamu Tachibana, Junkoh Yamashita, Howard L McLeod & Tsuyoshi Yokoi. (2004) A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 14:5, pages 329-332.
Crossref
Crossref
A Sparreboom, D F S Kehrer, R H J Mathijssen, R Xie, M J A de Jonge, P de Bruijn, A S T Planting, F A L M Eskens, C Verheij, G de Heus, A Klaren, S Zhang, T Verhaeghe, P A Palmer & J Verweij. (2004) Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor. British Journal of Cancer 90:8, pages 1508-1515.
Crossref
Crossref
Lisa C. Iacono, P. Kellie Turner & Clinton F. Stewart. 2004. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics
395
419
.
Zeshaan A Rasheed & Eric H Rubin. (2003) Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 22:47, pages 7296-7304.
Crossref
Crossref
Lyne Villeneuve, Hugo Girard, Louis-Charles Fortier, Jean-Francois Gagné & Chantal Guillemette. (2003) Novel Functional Polymorphisms in the UGT1A7 and UGT1A9 Glucuronidating Enzymes in Caucasian and African-American Subjects and Their Impact on the Metabolism of 7-Ethyl-10-hydroxycamptothecin and Flavopiridol Anticancer Drugs. Journal of Pharmacology and Experimental Therapeutics 307:1, pages 117-128.
Crossref
Crossref
Hideto Jinno, Mayumi Saeki, Yoshiro Saito, Toshiko Tanaka-Kagawa, Nobumitsu Hanioka, Kimie Sai, Nahoko Kaniwa, Masanori Ando, Kuniaki Shirao, Hironobu Minami, Atsushi Ohtsu, Teruhiko Yoshida, Nagahiro Saijo, Shogo Ozawa & Jun-ichi Sawada. (2003) Functional Characterization of Human UDP-Glucuronosyltransferase 1A9 Variant, D256N, Found in Japanese Cancer Patients. Journal of Pharmacology and Experimental Therapeutics 306:2, pages 688-693.
Crossref
Crossref
Yuichiro Watanabe, Miki Nakajima, Noriko Ohashi, Toshiyuki Kume & Tsuyoshi Yokoi. (2003) Glucuronidation of Etoposide in Human Liver Microsomes Is Specifically Catalyzed by UDP-Glucuronosyltransferase 1A1. Drug Metabolism and Disposition 31:5, pages 589-595.
Crossref
Crossref
R. NagasubramanianF. InnocentiM. J. Ratain. (2003) Pharmacogenetics in Cancer Treatment. Annual Review of Medicine 54:1, pages 437-452.
Crossref
Crossref
Brian Burchell. (2003) Genetic Variation of Human UDP-Glucuronosyltransferase. American Journal of PharmacoGenomics 3:1, pages 37-52.
Crossref
Crossref
Mayumi Saeki, Yoshiro Saito, Hideto Jinno, Kimie Sai, Kazuo Komamura, Kazuyuki Ueno, Shiro Kamakura, Masafumi Kitakaze, Kuniaki Shirao, Hironobu Minami, Atsushi Ohtsu, Teruhiko Yoshida, Nagahiro Saijo, Shogo Ozawa & Jun-ichi Sawada. (2003) Three Novel Single Nucleotide Polymorphisms in UGT1A9. Drug Metabolism and Pharmacokinetics 18:2, pages 146-149.
Crossref
Crossref
Hideto Jinno, Toshiko Tanaka-Kagawa, Nobumitsu Hanioka, Mayumi Saeki, Seiichi Ishida, Tetsuji Nishimura, Masanori Ando, Yoshiro Saito, Shogo Ozawa & Jun-ichi Sawada. (2003) Glucuronidation of 7-Ethyl-10-hydroxycamptothecin (SN-38), an Active Metabolite of Irinotecan (CPT-11), by Human UGT1A1 Variants, G71R, P229Q, and Y486D. Drug Metabolism and Disposition 31:1, pages 108-113.
Crossref
Crossref
P.Kellie Turner, Lisa C Iacono & Clinton F Stewart. 2003.
69
101
.
Miki Nakajima, Eriko Tanaka, Jun-Tack Kwon & Tsuyoshi Yokoi. (2002)
Characterization of Nicotine and Cotinine
N
-Glucuronidations in Human Liver Microsomes
. Drug Metabolism and Disposition 30:12, pages 1484-1490.
Crossref
Crossref
Yuichiro Watanabe, Miki Nakajima & Tsuyoshi Yokoi. (2002) Troglitazone Glucuronidation in Human Liver and Intestine Microsomes: High Catalytic Activity of UGT1A8 and UGT1A10. Drug Metabolism and Disposition 30:12, pages 1462-1469.
Crossref
Crossref
Miki Nakajima, Nozomi Sakata, Noriko Ohashi, Toshiyuki Kume & Tsuyoshi Yokoi. (2002) Involvement of Multiple UDP-glucuronosyltransferase 1A Isoforms in Glucuronidation of 5-(4′-hydroxyphenyl)-5-phenylhydantoin in Human Liver Microsomes. Drug Metabolism and Disposition 30:11, pages 1250-1256.
Crossref
Crossref
Yue-Hua Huang, Alema Galijatovic, Nghia Nguyen, Donald Geske, Deirdre Beaton, Judith Green, Mark Green, Wilbert H. Peters & Robert H. Tukey. (2002) Identification and functional characterization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGT1A8*3. Pharmacogenetics 12:4, pages 287-297.
Crossref
Crossref